IUGNF: AI 评分 41/100 — AI 分析 (4月 2026)

Imugene Limited is a clinical-stage immuno-oncology company based in Australia, focusing on developing immunotherapies to activate the immune system to fight cancer. Their lead product, HER-Vaxx, targets HER2-positive cancers and is currently in Phase 1b/2 trials for gastric cancer.

Key Facts: AI Score: 41/100 Sector: Healthcare

公司概况

概要：

Imugene Limited is an Australian clinical-stage immuno-oncology company specializing in the development of cancer immunotherapies, particularly vaccines like HER-Vaxx targeting HER2-positive cancers. With ongoing clinical trials and strategic collaborations, Imugene aims to harness the immune system to eradicate tumors, positioning itself in the competitive biotechnology landscape.

IUGNF是做什么的？

Imugene Limited, founded in 1986 and headquartered in Sydney, Australia, is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies. The company's primary objective is to activate the immune system of cancer patients, enabling it to recognize and eradicate tumors. Imugene's lead product, HER-Vaxx, is a HER2-positive cancer vaccine designed to stimulate a polyclonal antibody response against HER2/neu receptors, which are commonly overexpressed in gastric and breast cancers. HER-Vaxx is currently undergoing a Phase 1b/2 clinical study for gastric cancer. In addition to HER-Vaxx, Imugene is developing PD1-Vaxx, a cancer vaccine intended to induce the body to produce polyclonal antibodies that block PD-1 signaling, a key immune checkpoint. The company is also working on CF33, a combination of genomic sequences from various vaccinia virus strains engineered to generate a potent oncolytic virus. Imugene has established research collaborations to expand its therapeutic capabilities, including a partnership with Celularity Inc. to combine Imugene's CD19 oncolytic virus technology with Celularity's CyCART-19, a CD19-targeting allogeneic chimeric antigen receptor T-cell therapy, for the treatment of solid tumors. Furthermore, Imugene has a strategic collaboration with Eureka Therapeutics, Inc. to develop novel cancer therapies. Imugene operates primarily in Australia, focusing on early-stage clinical development and strategic partnerships to advance its pipeline.

IUGNF的投资论点是什么？

Imugene Limited presents a high-risk, high-reward investment opportunity within the immuno-oncology sector. The company's valuation is approximately $70 million, with a negative P/E ratio of -0.92, reflecting its current lack of profitability as a clinical-stage company. The primary value driver is the successful development and commercialization of its lead product, HER-Vaxx, currently in Phase 1b/2 trials. Positive clinical trial data could serve as a significant catalyst, potentially leading to partnerships or acquisition. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding, given the company's negative profit margin of -1864.1%. The company's high beta of 2.48 indicates significant volatility relative to the market.

IUGNF在哪个行业运营？

Imugene operates within the competitive immuno-oncology market, a rapidly growing segment of the biotechnology industry. The global immuno-oncology market is projected to reach billions of dollars by 2030, driven by increasing cancer prevalence and advancements in immunotherapy approaches. Key trends include the development of personalized cancer vaccines, oncolytic viruses, and combination therapies. Imugene's focus on HER2-positive cancers and strategic collaborations positions it to potentially capitalize on these trends, although it faces competition from larger, more established pharmaceutical companies.

Biotechnology

Healthcare

IUGNF有哪些增长机遇？

HER-Vaxx Clinical Development: The successful completion of Phase 1b/2 trials for HER-Vaxx in gastric cancer represents a significant growth opportunity. Positive data could lead to accelerated development, potential partnerships, and eventual commercialization. The gastric cancer market is substantial, with a global market size projected to reach $4.1 billion by 2027. Timeline: Ongoing clinical trials with data readouts expected in the next 12-24 months.
PD1-Vaxx Development: Advancing PD1-Vaxx, a cancer vaccine targeting the PD-1 pathway, offers a significant growth avenue. Blocking PD-1 signaling is a validated approach in immuno-oncology, and a successful vaccine could address a broad range of cancers. The market for PD-1/PD-L1 inhibitors is substantial, exceeding $25 billion annually. Timeline: Preclinical and early-stage clinical development over the next 2-3 years.
CF33 Oncolytic Virus Platform: The CF33 oncolytic virus platform has the potential to be a versatile therapeutic approach for various cancers. Oncolytic viruses are gaining traction as a promising modality in immuno-oncology. The global oncolytic virus therapy market is projected to reach $749 million by 2027. Timeline: Ongoing preclinical and early clinical studies.
Strategic Collaborations: Leveraging strategic collaborations, such as the partnership with Celularity Inc., to develop combination therapies can accelerate pipeline development and expand therapeutic applications. Combining Imugene's oncolytic virus technology with Celularity's CAR-T cell therapy could create synergistic effects in treating solid tumors. Timeline: Ongoing research and development efforts with potential clinical trials in the next 1-2 years.
Expansion into New Cancer Targets: Expanding the pipeline to include new cancer targets beyond HER2 and PD-1 can broaden Imugene's market opportunity and reduce reliance on specific therapeutic areas. Identifying novel targets and developing corresponding immunotherapies could drive long-term growth. Timeline: Ongoing research and development efforts to identify and validate new cancer targets.

Market capitalization of $0.07 billion reflects its position as a small-cap biotechnology company.
Negative P/E ratio of -0.92 indicates the company is currently not profitable, typical for clinical-stage biotechs.
Gross margin of -65.9% highlights the high cost of research and development relative to current revenue streams.
Beta of 2.48 suggests the stock is significantly more volatile than the overall market.
No dividend yield reflects the company's focus on reinvesting earnings into research and development.

IUGNF提供哪些产品和服务？

Develops HER-Vaxx, a HER2-positive cancer vaccine targeting gastric and breast cancer.
Creates PD1-Vaxx, a cancer vaccine designed to block PD-1 signaling.
Engineers CF33, an oncolytic virus platform for cancer treatment.
Conducts Phase 1b/2 clinical trials for HER-Vaxx in gastric cancer.
Collaborates with Celularity Inc. to develop combination therapies for solid tumors.
Partners with Eureka Therapeutics, Inc. to develop novel cancer therapies.
Focuses on activating the immune system to eradicate tumors.

IUGNF如何赚钱？

Develops and patents novel cancer immunotherapies.
Conducts preclinical and clinical trials to evaluate the safety and efficacy of its products.
Seeks strategic collaborations and partnerships to accelerate development and commercialization.
Out-licenses or sells its technologies to larger pharmaceutical companies.

Cancer patients participating in clinical trials.
Hospitals and medical centers conducting clinical trials.
Pharmaceutical companies seeking to license or acquire Imugene's technologies.
Research institutions collaborating on immunotherapy development.

Proprietary immunotherapy technologies, including HER-Vaxx, PD1-Vaxx, and CF33.
Patent protection for its key products and technologies.
Strategic collaborations with leading research institutions and pharmaceutical companies.
Expertise in immuno-oncology and cancer vaccine development.

什么因素可能推动IUGNF股价上涨？

Upcoming: Data readout from the Phase 1b/2 clinical trial of HER-Vaxx in gastric cancer (expected in the next 12-24 months).
Upcoming: Initiation of clinical trials for PD1-Vaxx (expected within the next 2-3 years).
Ongoing: Progress in strategic collaborations with Celularity Inc. and Eureka Therapeutics, Inc.
Ongoing: Advancement of the CF33 oncolytic virus platform through preclinical and early clinical studies.
Ongoing: Identification and validation of new cancer targets for immunotherapy development.

IUGNF的主要风险是什么？

Potential: Clinical trial failures for HER-Vaxx, PD1-Vaxx, or CF33.
Potential: Regulatory hurdles and delays in obtaining marketing approvals.
Ongoing: Competition from larger pharmaceutical companies with greater resources.
Ongoing: Need for additional funding and potential dilution of existing shareholders.
Ongoing: Dependence on key personnel and strategic collaborations.

IUGNF的核心优势是什么？

Proprietary immunotherapy technologies.
Strategic collaborations with leading institutions.
Experienced management team in immuno-oncology.
Strong patent portfolio.

IUGNF的劣势是什么？

Limited financial resources as a clinical-stage company.
Dependence on successful clinical trial outcomes.
High cash burn rate.
Negative profit margin.

IUGNF有哪些机遇？

Successful completion of clinical trials for HER-Vaxx and PD1-Vaxx.
Expansion into new cancer targets and therapeutic areas.
Out-licensing or partnering with larger pharmaceutical companies.
Growing demand for immuno-oncology therapies.

IUGNF面临哪些威胁？

Clinical trial failures.
Regulatory hurdles and delays.
Competition from larger pharmaceutical companies.
Need for additional funding and potential dilution.

IUGNF的竞争对手是谁？

Bio-Senze Therapeutics Inc — Focuses on developing innovative cancer therapies. — (BSEM)
Cellectis SA — Develops allogeneic CAR T-cell therapies for cancer. — (CLTEF)
Hutchison China MediTech Ltd — Develops and commercializes innovative medicines in China and internationally. — (HSCHF)
Kintara Therapeutics Inc — Focuses on developing new cancer therapies for unmet medical needs. — (KNTPF)
Mesoblast Ltd — Develops and commercializes allogeneic cellular medicines. — (MSCLF)

Key Metrics

MoonshotScore: 41/100

Company Profile

CEO: Leslie Chong
Headquarters: Sydney, AU
Employees: 5
Founded: 2019

AI Insight

AI analysis pending for IUGNF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Imugene Limited do?

Imugene Limited is a clinical-stage immuno-oncology company focused on developing a range of immunotherapies designed to activate the immune system to fight cancer. Their lead product, HER-Vaxx, is a HER2-positive cancer vaccine currently in Phase 1b/2 clinical trials for gastric cancer. The company also develops PD1-Vaxx, a cancer vaccine targeting the PD-1 pathway, and CF33, an oncolytic virus platform. Imugene collaborates with other companies to develop combination therapies, aiming to provide innovative solutions for cancer treatment.

What do analysts say about IUGNF stock?

As of March 15, 2026, there is no readily available analyst consensus on IUGNF stock due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the company's clinical trial progress, financial stability, and competitive landscape. Key valuation metrics include market capitalization and cash burn rate. Growth considerations include the successful development and commercialization of its lead product candidates.

What are the main risks for IUGNF?

The main risks for Imugene Limited include the potential for clinical trial failures, regulatory hurdles, and competition from larger pharmaceutical companies. As a clinical-stage company, Imugene is heavily reliant on the successful development of its product candidates. The company also faces the risk of needing additional funding, which could dilute existing shareholders. Investing in IUGNF carries significant risks due to its OTC listing and small market capitalization.